Dr. Koffman’s Bispecific T-cell Engager (epcoritamab) Trial for CLL Blog
Despite an aggressive flavor of CLL, I enjoyed a 7+ year remission from my PCI-32765 (now known as ibrutinib), phase 1 trial, and 5+ years from my JCAR-014 (the parent of liso-cel) phase 1 trial. Now I am hoping that I get a similar response from my epcoritamab (EPCORE™) trial with this new bispecific T cell engaging monoclonal. Join and learn with me as I blog about my experiences.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells
The beginning of a new calendar year is not a good reason to make radical changes, but it may mark a timely moment to reflect on what’s gone well and what could be better going forward.
With my CLL well controlled, my IVIG aboard, and my epcoritamab injections now every two weeks, the timing is perfect. I am in good shape heading to ASH.
Hippocrates said: “Art is long, and life is short.” The creation outlives its creator. How does that translate to my work and the work of the CLL Society?
I have been mostly silent on my blog as there has not been much to report related to my phase 1 clinical trial for my relapsed chronic lymphocytic leukemia (CLL). No news is good news.
My last three doses of full-strength epcoritamab (48 mg) have been nonevents. There was some mild fatigue and itching the next day, but there is really nada to report. No cytokine release syndrome (CRS), for sure. All good.
I am very close to complete remission, with only one node still greater than 1.5 cm in its longest diameter.
I will soon be rescanned to see if my total of seven doses, with the last three being the full therapeutic dose of 48 mg of epcoritamab, has shrunken my lymph nodes.
Despite mild persistent night sweats and disturbed sleep, I am enjoying and learning much at iwCLL (international workshop on CLL) in Boston.
It’s been a challenging seven weeks since starting my trial of epcoritamab, a bispecific T cell engaging (BITE) monoclonal antibody.
After seven weeks of cytokine release (CRS) and way too many steroids, I have finally gone almost four days with no fever without the antipyretic benefits of Tylenol or steroids
Brian has asked me, again, to update you on his progress with his epcoritamab trial. Until Monday, Brian had a fever every day. He wasn’t on steroids since Sept. 5.
Dr. Koffman has asked that I help him with his blog again. He has had a rough few days, and he felt it was time to give an update on his clinical trial, even though it may be short.
My first 28-day cycle of the four-dose ramp-up of epcoritamab for my chronic lymphocytic leukemia (CLL) can’t fade away fast enough for my liking.
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
